1.Research Progress on Application of Cerebrospinal Fluid Liquid Biopsy in Brain Metastasis from Lung Cancer
Yidie WANG ; Jie HUANG ; Xueqin CHEN
Cancer Research on Prevention and Treatment 2026;53(7):572-576
Lung cancer is one of the most common malignant tumors. Brain metastasis, especially meningeal metastasis, is a fatal complication of lung cancer. The sensitivity of traditional diagnostic methods for this disease is limited. As a new technology, cerebrospinal fluid liquid biopsy can noninvasively and dynamically detect the molecular characteristics of intracranial tumors. Cerebrospinal fluid directly contacts the central nervous system lesions. It contains more unique and representative tumor-derived molecular information compared with those obtained from other body fluids such as blood for lung cancer meningeal metastasis, thus remarkably improving the diagnosis and personalized treatment of lung cancer meningeal metastasis. This work reviews the research progress on cerebrospinal fluid liquid biopsy in lung cancer brain metastasis and explores its value in guiding targeted therapy, delineating drug resistance, and evaluating prognostic progression to provide new directions for the clinical diagnosis and treatment of lung cancer brain metastasis.
2.Evolution of global disease burden,risk factors and trend projection of chronic obstructive pulmonary disease among individuals under 50 years old from 1990 to 2021
Yide WANG ; Hongxia DUAN ; Yingqi WANG ; Yidie BAO ; Linhong JIANG ; Xiaoyu HAN ; Peijun LI ; Weibing WU ; Xiaodan LIU
Journal of Army Medical University 2025;47(12):1388-1400
Objective To systematically assess the spatiotemporal distribution,risk factors,and future trends of chronic obstructive pulmonary disease(COPD)among individuals under 50 years of age globally from 1990 to 2021 based on Global Burden of Disease(GBD)data in order to provide support for the formulation of prevention and control strategies of the disease.Methods The GBD data from 1990 to 2021 were analyzed for the incidence,mortality,disability-adjusted life years(DALYs),and estimated annual percentage change(EAPC)of COPD in<50-year-old individuals across 204 countries and regions.The data were stratified by age,sex,region,country,and sociodemographic index(SDI).The COPD trends until 2035 were predicted.Results In 2021,the global incidence of early-onset COPD was estimated at 2.5 million cases(95%uncertainty interval:2.09~2.96 million),representing a 50.55%increase compared to 1990.Significant regional heterogeneity was observed,with low SDI regions experiencing a 134.08%increase,whereas high SDI regions exhibited a rise-then-fall trend.Risk factor analysis identified environmental and occupational exposures(air pollution,ambient ozone pollution,household air pollution from solid fuels,etc.)and smoking as the primary etiological factors.Notably,household solid fuel exposure accounted for 50.90%of COPD-related deaths in low SDI regions,compared to only 0.03%in high SDI regions.Projections indicated that by 2035,the global burden of early-onset COPD will increase to 2.59 million cases.Conclusion The global disease burden of COPD among people under 50 years increased significantly from 1990 to 2021,with pronounced disparities across regions and socioeconomic levels.COPD deaths in low-SDI regions are strongly associated with solid fuel exposure and particulate matter pollution,and these regions are expected to remain the main drivers of global COPD incidence growth through 2035.
3.Mining and analysis of busulfan adverse drug events signals based on FAERS database
Guangfei WANG ; Junqi ZHANG ; Yidie HUANG ; Yueyue WANG ; Xiaowen ZHAI ; Zhiping LI
Chinese Journal of Pharmacoepidemiology 2024;33(3):259-268
Objective To study adverse drug events(ADEs)of busulfan the U.S.Food and Drug Administration Adverse Event Reporting System(FAERS),and to mine the potential ADE signals,so as to provide reference for the safe drug use in clinical practice.Methods Data from the first quarter of 2004 to the first quarter of 2023 were retrieved from the FAERS database,and ADE records for busulfan as a primary suspect drug were obtained through data cleaning and standardization of target drug names.Risk signals for busulfan ADEs were mined based on the reporting odds ratio method,the proportional reporting ratio method,and Medicines and Healthcare Products Regulatory Agency method.The information component method was used to assess the intense of the risk signals.The ADEs were systematically classified according to Medical Dictionary for Regulatory Activities(MedDRA),and two ranking sequence of busulfan ADEs were generated by signal occurrence frequency and signal intense,respectively.Results A total of 20 326 ADE records were collected,involving 5 615 patients with 556 related ADE signals,of which 117 were newly reported as compared to those in the drug instruction of busulfan.Male patients accounted for a higher proportion than female patients(40.71%vs.30.74%).The main population of patients were younger than 18 years old(31.56%).The reports were most reported by physicians(33.71%)and other health professionals(24.35%)as well as pharmacists(23.86%),mainly from the United States(29.69%),Japan(15.78%),and France(11.79%).The top five ADEs in terms of occurrence frequency were busulfan use in unapproved indications,hepatic veno-occlusive disease(HVOD),mucosal inflammation,cytomegalovirus infection,and graft versus host disease.The top five ADEs in terms of signal intense were HVOD,acute graft versus host disease,veno-occlusive disease,graft versus host disease,and chronic graft versus host disease.The ADE signals involves 23 system organ classes.The top three SOCs in terms of the number of ADE signals were infections/infestations,investigations and neoplasms benign/malignant/unspecified(include cysts and polyps).Conclusion When busulfan is used in clinic,attention should be paid to its adverse events in hepatic veno-occlusive disease,infections,graft versus host disease,neurotoxicity,and venous thromboembolism,which are likely to cause serious consequences.The clinical pharmacists can assist clinicians to make prevention plans in case of busulfan ADEs,so as to improve the safety of busulfan use in clinic.
4.Rehabilitation effects of traditional Chinese medicine exercise therapy on chronic obstructive pulmonary disease
Jiacheng SHI ; Peijun LI ; Linhong JIANG ; Yingqi WANG ; Yidie BAO ; Xinliao DENG ; Hongxia DUAN ; Yuchen HE ; Yuan ZHU ; Xiaodan LIU
Journal of Navy Medicine 2024;45(5):549-554
Chronic obstructive pulmonary disease(COPD)has become a common chronic disease in the adult in recent years,and more attention has been gradually paid to its prevention and treatment.This paper reviewed the clinical studies about the effect of traditional Chinese medicine(TCM)exercise therapy on COPD,and indicated that TCM exercise therapy can improve the rehabilitation of COPD patients.TCM exercise therapies,such as Tai Chi,Wuqinxi,Baduanjin,and Liuzijue,have been shown to significantly improve lung function,inflammation levels,and exercise capacity in COPD patients in recent studies.Tai Chi significantly improves patient's respiratory problems although lung function indices are not changed.Liuzijue enhances the strength and endurance of respiratory muscles and limbs.Baduanjin helps to improve patient's cognitive and emotional states.Overall,TCM exercise therapy provides an effective rehabilitation option for COPD patients.However,more clinical controlled trials are needed to further confirm their effectiveness and to develop appropriate rehabilitation programs for COPD patients.
5.Research progress of organoid models in bladder cancer
Wei HE ; Yidie YING ; Maoyu WANG ; Shuxiong ZENG ; Chuanliang XU
Chinese Journal of Clinical Oncology 2024;51(1):41-44
Organoids are novel in vitro models that can effectively simulate the complexities of tumor microenvironments.Compared to tra-ditional preclinical models,organoids retain most of the histological and molecular properties of the primary tumor;therefore,they are more useful for studying tumor heterogeneity,underlying functional pathways,and immune microenvironments as well as for research on biomarker discovery,drug screening,and individual chemotherapy.Furthermore,current limitations,challenges such as low modeling suc-cess rates,high costs,and lack of standardization are expected to be overcome by continued innovations in bioengineering technologies and interdisciplinary integration.This article reviews the advantages,establishment processes,and prospects and challenges associated with the clinical application of organoids in bladder cancer.
6.Efficacy of cutaneous ureterostomy-flap embedding in radical cystectomy plus urinary diversion in 10 cases
Xufeng YU ; Meimian HUA ; Shuxiong ZENG ; Qing CHEN ; Ziwei WANG ; Yidie YING ; Maoyu WANG ; Chen ZHANG ; Yi WANG ; Chuanliang XU
Journal of Modern Urology 2024;29(12):1099-1103
[Objective] To explore the clinical application of cutaneous ureterostomy-flap embedding in radical cystectomy plus urinary diversion. [Methods] The clinical data of 10 patients with bladder cancer treated with this method in our hospital during Feb.and May 2023 were involved.Cutaneous ureterostomy-flap embedding was used in urinary diversion.The stoma-free rate and stenosis rate of stomas within 1 year postoperatively, differences in renal function indicators 1 day before operation and 1 year after operation, urinary diversion-related complications within 6 months postoperatively, including hydronephrosis, urinary tract infections, renal stones were analyzed. [Results] All surgeries were successfully completed.At 1 year postoperatively, renal function indicators showed no significant difference compared to preoperative levels (P>0.05). At 6 months postoperatively, 1 patient developed renal stones, successfully treated with surgery; 2 had urinary tract infection, recovered after antibiotic treatment; 2 had mild unilateral hydronephrosis, alleviated with conservative management.At 1 year postoperatively, the catheter-free rate was 80%(8/10), with no worsening of hydronephrosis or occurrence of ureteral obstruction, and the stent placement duration ranged from 97 to 211 days, average (151.63±42.47) days.The ureteral stent was not removed in 2 patients within 1 year, so the stoma stenosis rate was 20%(2/10). [Conclusion] The application of flap embedding in urinary diversion following radical cystectomy is a simple and safe procedure, with few postoperative complications, high success rate of stent removal, and overall favorable outcomes.

Result Analysis
Print
Save
E-mail